Beltway Confidential

Inflexible, bureaucratic FDA is dragging its feet on coronavirus response

By Tom Rogan
Published March 20, 2020 5:54pm ET
Add Washington Examiner on Google
Inflexible, bureaucratic FDA is dragging its feet on coronavirus response
President Trump signed into law the FDA Reauthorization Act of 2017 on Friday. It reauthorizes a program in which drug and device makers pay the FDA a fee for every new product application, and the agency uses that money to hire more people and speed up approvals. (AP Photo/Andrew Harnik, File) | Andrew Harnik

President Trump is extolling his administration’s coronavirus response effort. To that end, Trump says he has massively cut red tape to maximize the government’s efficiency.

It sounds good, but Trump hasn’t done enough on this score.

Already a print subscriber? Click here to login/register your account

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.

Tag:

China COVID-19 Donald Trump FDA Regulations